Studies on genetic and microbiologicail quality of human tumor xenografts lines as a tool for animal experiments
作为动物实验工具的人类肿瘤异种移植物系的遗传和微生物质量研究
基本信息
- 批准号:05454690
- 负责人:
- 金额:$ 3.52万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (B)
- 财政年份:1993
- 资助国家:日本
- 起止时间:1993 至 1995
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Background : Human tumor xenografts (HTXs) are a useful tool for animal experiments especially for evaluation of new antitumor drugs. We have been establishing HTXs, and have developed tumor chemosensitivity panels for new drug evaluation using them.Purpose : With regard to quality control (problems in chanes into mouse type tumors and/or artificial cross-contamination among tumor lines), we studied genetic profiling, and effects of long-term passaging on tumor properties such as growth and chemosensitivities, and we discuss the use of cryopreservation stock of HTXs and periodic replacement in order to maintain reproducibility of the experimental results. Methods : We examined isozyme markers and DNA fingerprinting to identify species and individuality of the tumors, respectively. Growth curves and sensitivities to antitumor drugs were examined using HTXs with different passaging in nude mice. Results : Among the tumors we maintained, five human tumors were found to have changed to mouse origin from their isozyme markers and were excluded. We identified the individuality of tumors which we used for the chemosensitivity panels by DNA fingerprinting, and their properties were stable for long-term passaging in nude mice. However, growth speed and chemosensitivities to drugs were altered with long-term passaging, although DNA fingerprint analysis did not show any obvious changes with passaging. Conclusions : Genetic profiling, such as isozyme markers and DNA fingerprinting, is useful for identify individuality of experimental HTXs, and tumors should be renewed periodically even when there are no signs of artificial contamination when they are used in experiments which require continuous reproducibility of experimental results.
背景:人类肿瘤异种移植物(HTX)是一种非常有用的动物实验工具,尤其是用于评价新的抗肿瘤药物。我们一直在建立HTX,并开发了用于新药评估的肿瘤化疗敏感性面板。目的:关于质量控制(转化为小鼠型肿瘤和/或肿瘤系间人为交叉污染的问题),我们研究了遗传谱,以及长期传代对肿瘤性质如生长和化学敏感性的影响,我们讨论了使用HTX的冷冻保存储备和定期更换,以保持实验结果的重现性。方法:采用同工酶标记和DNA指纹图谱技术对肿瘤进行种属鉴定和个体鉴别。用不同代次的HTX在裸鼠体内观察其生长曲线及对抗癌药物的敏感性。结果:在我们保留的肿瘤中,发现5个人肿瘤从其同工酶标记物改变为小鼠来源,并被排除。我们通过DNA指纹鉴定了用于化疗敏感性小组的肿瘤的个体性,并且它们的性质在裸鼠中长期传代是稳定的。然而,生长速度和药物敏感性的改变与长期传代,虽然DNA指纹分析没有显示任何明显的变化与传代。结论:基因谱分析,如同工酶标记和DNA指纹,是有用的,以确定实验HTX的个性,和肿瘤应定期更新,即使当没有人为污染的迹象时,它们被用于实验中,需要实验结果的连续再现性。
项目成果
期刊论文数量(62)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hiroshi Kijima: "Stability of ras oncogene mutation in the human tumor xenografts through serial passage." Anticancer Res.14. 2583-2588 (1994)
Hiroshi Kijima:“通过连续传代,人类肿瘤异种移植物中 ras 癌基因突变的稳定性。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Tokuda, Y., Ohnishi, Y., Shimamura, K., Iwasawa, M., Yoshimura, M., Yeyama, Y., Tamaoki, N., Tajima, T.and Mitomi, T.: "In vitro and in vivo anti-tumor effects of a humanized monoclonal antibody against c-erbB-2 product." Br.J.Cancer. (in press). (1996)
Tokuda, Y.、Ohnishi, Y.、Shimamura, K.、Iwasawa, M.、Yoshimura, M.、Yeyama, Y.、Tamaoki, N.、Tajima, T. 和 Mitomi, T.:“体外和体内
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ohnishi, Y., Yoshimura, M.and Ueyama, Y.: "Lactic dehydrogenase virus (LDHV) contamination in human tumor xenografts and its elimination." J.Natl.Cancer Inst.87. 538-539 (1995)
Ohnishi, Y.、Yoshimura, M. 和 Ueyama, Y.:“人类肿瘤异种移植物中的乳酸脱氢酶病毒 (LDHV) 污染及其消除。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yasuyuki Ohnishi: "Practical role of genetic profiling and presevration stack of human tumor xenograft line as a tool in animal experiments for antitumordrug evaluation" Lab.Anim.sabmitted. (1996)
Yasuyuki Ohnishi:“人类肿瘤异种移植物系的基因分析和保存堆栈作为抗肿瘤药物评估动物实验工具的实际作用”Lab.Anim.sabished。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yasuyuki Ohnishi: "Practical role of genetic profiling and presevvation sitock of humman tumorxenogrft eine as a tool in animal experiments for antitumordrug evaluotion" Lab. Anim.(Sabmitted). (1996)
Yasuyuki Ohnishi:“人类肿瘤异种移植物的基因分析和保存作为抗肿瘤药物评估动物实验工具的实际作用”实验室。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OHNISHI Yasuyuki其他文献
OHNISHI Yasuyuki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OHNISHI Yasuyuki', 18)}}的其他基金
Establishment of human tumor xenotransplantation models as a pre-clinical assisting tool for translational research
建立人类肿瘤异种移植模型作为转化研究的临床前辅助工具
- 批准号:
13480283 - 财政年份:2001
- 资助金额:
$ 3.52万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Studies on in vivo evaluation system of treatment for cancer prevention and progression using cancer prone gene-engineered mice
使用易患癌症的基因工程小鼠研究癌症预防和进展治疗的体内评价系统
- 批准号:
12558097 - 财政年份:2000
- 资助金额:
$ 3.52万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Knock-down mouse, a novel gene engineering mouse for use as a disease model
击倒小鼠,一种用作疾病模型的新型基因工程小鼠
- 批准号:
11480251 - 财政年份:1999
- 资助金额:
$ 3.52万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Improvement of human tumor xenograft-mouse model as a preclinical evaluation system of new drugs discovered and developed by the novel strategy against cancer
人类肿瘤异种移植小鼠模型的改进作为抗癌新策略发现和开发的新药的临床前评价系统
- 批准号:
08458278 - 财政年份:1996
- 资助金额:
$ 3.52万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
A new approach for prediction of clinical efficacy of anticancer drugs based on toxicokinetic and pharmacokinetic analysis
基于毒代动力学和药代动力学分析预测抗癌药物临床疗效的新方法
- 批准号:
07558117 - 财政年份:1995
- 资助金额:
$ 3.52万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
相似国自然基金
癌干细胞形成过程中microRNA的表达及其功能研究
- 批准号:30971625
- 批准年份:2009
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
Greatwall in replication stress/DNA damage responses and oral cancer resistance
长城在复制应激/DNA损伤反应和口腔癌抵抗中的作用
- 批准号:
10991546 - 财政年份:2024
- 资助金额:
$ 3.52万 - 项目类别:
KRAS inhibitors prime cancer cells for macrophage-mediated destruction
KRAS 抑制剂可引发巨噬细胞介导的破坏癌细胞
- 批准号:
10638364 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Fatty Acid Metabolic Regulation of Anti-Tumor Immunity Against Irradiated Glioblastoma
脂肪酸代谢调节抗辐射胶质母细胞瘤的免疫
- 批准号:
10638744 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
- 批准号:
10638347 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancer
RNA m6A修饰在前列腺癌发病及耐药中的作用及机制
- 批准号:
10638634 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Characterizing antibody responses to HIV-1 vaccination in next-generation immune humanized mice
表征下一代免疫人源化小鼠对 HIV-1 疫苗接种的抗体反应
- 批准号:
10673292 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Pathophysiology and prevention of degeneration of heterograft biomaterials due to advanced glycation end products and serum protein infiltration
由于晚期糖基化终产物和血清蛋白浸润导致异种移植生物材料变性的病理生理学和预防
- 批准号:
10679910 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris
桥粒芯糖蛋白 3 嵌合自身抗体受体 T 细胞 (DSG3-CAART) 对粘膜寻常型天疱疮的免疫调节作用
- 批准号:
10679911 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Investigating hematopoietic stem cell dysfunction during sickle cell disease
研究镰状细胞病期间的造血干细胞功能障碍
- 批准号:
10681829 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:














{{item.name}}会员




